Morikazu Amano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Morikazu Amano has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Takeo Hasegawa
Suzuka University of Medical Science
6 shared publicationsHajime Monzen
Ohtsu Red Cross Hospital
5 shared publicationsSatoshi Ando
Department of Health Science. Graduate School of Suzuka University of Medical Science
4 shared publicationsItsuo Yamamoto
Department of Radio-Frequency Research Center, Yamamoto Vinita Co
3 shared publicationsKayoko Maeda
Department of Health Science. Graduate School of Suzuka University of Medical Science
3 shared publicationsTohru Takahashi
Department of RI Research Center, Kansai Medical University
3 shared publications
Latest Publications
- 25 February 2007
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 12 (1) , 42-47
Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay
The present study investigated whether treatment with anginex, a novel antiangiogenic peptide, could block re-vascularization after radiation treatment. A squamous cell (SCCVII) xenograft tumor mouse model was employed to assess the effects of anginex given post-radiation on tumor growth, microvessel density (MVD), and oxygen levels. The oxygen status was determined by the partial pressure of O2. Tumors in untreated mice increased threefold in 7.0 days, anginex-treated tumors (10 mg/kg intraperitoneal, twice) required 7.3 ± 0.9 days, and tumors exposed to 8-Gy radiation increased threefold over 11 days. Combination treatment of anginex and radiation caused the tumors to grow threefold in 16.1 ± 1.6 days, a delay which was significant and deemed supra-additive. Oxygen levels in tumors treated by stand-alone or combination therapies were significantly reduced; for example from 19.5 ± 4.9 mmHg in controls to 9.7 ± 1.9 mmHg in combination-treated, size-matched tumors. In addition, immunohistochemistry showed a decrease in MVD in the tumors treated with anginex, radiation, or the combination. These results suggest that a combination of anginex and radiation can greatly affect the amount of functional vasculature in tumors and prolong radiation-induced tumor regression. Antiangiogenesis therapy with anginex, in addition to radiotherapy, will be useful by blocking angiogenesis-dependent regrowth of vessels.
- 25 February 2007
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 12 (1) , 42-47
Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay
The present study investigated whether treatment with anginex, a novel antiangiogenic peptide, could block re-vascularization after radiation treatment. A squamous cell (SCCVII) xenograft tumor mouse model was employed to assess the effects of anginex given post-radiation on tumor growth, microvessel density (MVD), and oxygen levels. The oxygen status was determined by the partial pressure of O2. Tumors in untreated mice increased threefold in 7.0 days, anginex-treated tumors (10 mg/kg intraperitoneal, twice) required 7.3 ± 0.9 days, and tumors exposed to 8-Gy radiation increased threefold over 11 days. Combination treatment of anginex and radiation caused the tumors to grow threefold in 16.1 ± 1.6 days, a delay which was significant and deemed supra-additive. Oxygen levels in tumors treated by stand-alone or combination therapies were significantly reduced; for example from 19.5 ± 4.9 mmHg in controls to 9.7 ± 1.9 mmHg in combination-treated, size-matched tumors. In addition, immunohistochemistry showed a decrease in MVD in the tumors treated with anginex, radiation, or the combination. These results suggest that a combination of anginex and radiation can greatly affect the amount of functional vasculature in tumors and prolong radiation-induced tumor regression. Antiangiogenesis therapy with anginex, in addition to radiotherapy, will be useful by blocking angiogenesis-dependent regrowth of vessels.
- Open Access
- 1 January 2005
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 21 (2) , 103-112
Comparisons of the Suppressive Effects on Tumor Growth by Different Combinations of Administration of Arsenic Trioxide and Hyperthermia
- 1 January 2005
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 21 (2) , 103-112
Open AccessComparisons of the Suppressive Effects on Tumor Growth by Different Combinations of Administration of Arsenic Trioxide and Hyperthermia
- Open Access
- 1 January 2005
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 21 (1) , 33-45
The Activation of Immunological Activity and Anti-tumor Effects by Mild Hyperthermia
- 1 January 2005
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 21 (1) , 33-45
Open AccessThe Activation of Immunological Activity and Anti-tumor Effects by Mild Hyperthermia
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 46 (4) , 373-378
Increase in Tumor Oxygenation and Potentiation of Radiation Effects Using Pentoxifylline, Vinpocetine and Ticlopidine Hydrochloride
The purpose of the present study was to investigate the effects of Pentoxifylline (PTX), Vinpocetine (VPT) and Ticlopidine Hydrochloride (TCD), used
- 1 January 2005
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 46 (4) , 373-378
Open AccessIncrease in Tumor Oxygenation and Potentiation of Radiation Effects Using Pentoxifylline, Vinpocetine and Ticlopidine Hydrochloride
The purpose of the present study was to investigate the effects of Pentoxifylline (PTX), Vinpocetine (VPT) and Ticlopidine Hydrochloride (TCD), used
- 8 October 2004
- Vol. 22 (4) , 205-11
Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor.
Arsenic trioxide (ATO) has been reported to be an effective chemotherapeutic agent for acute promyelocytic leukemia (APL), and, recently, anti-tumor effect has been demonstrated in solid tumors. However, little is known about the mechanism of action of the ATO effect on solid tumor. We investigated the anti-vascular effect of ATO and the potential of combining ATO with radiation therapy. We studied the anti-vascular effect of ATO and radiosensitization of squamous cell carcinoma (SCC) VII murine tumors of C3H mice. The anti-vascular effect was examined using magnetic resonance imaging(MRI), and radiosensitivity was studied by clonogenic assay and tumor growth delay. Histopathological changes of the tumors after various treatments were also observed with hematoxylin and eosin (H&E) staining. Necrosis and blood flow changes in the central region of tumors in the hind limbs of the animals were observed on T2-weighted imaging after an i.p. injection of 8 mg/kg of ATO alone. ATO exposure followed by radiation decreased the clonogenic survival of SCC VII cells compared with either treatment alone. Tumor growth delay after 10-20 Gy of radiation alone was increased slightly compared with control tumors, but the combination of ATO injection 2 hours before exposure to 20 Gy of radiation significantly prolonged tumor growth delay by almost 20 days. The results suggest that ATO and radiation can enhance the radiosensitivity of solid tumor.
- 8 October 2004
- Vol. 22 (4) , 205-11
Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor.
Arsenic trioxide (ATO) has been reported to be an effective chemotherapeutic agent for acute promyelocytic leukemia (APL), and, recently, anti-tumor effect has been demonstrated in solid tumors. However, little is known about the mechanism of action of the ATO effect on solid tumor. We investigated the anti-vascular effect of ATO and the potential of combining ATO with radiation therapy. We studied the anti-vascular effect of ATO and radiosensitization of squamous cell carcinoma (SCC) VII murine tumors of C3H mice. The anti-vascular effect was examined using magnetic resonance imaging(MRI), and radiosensitivity was studied by clonogenic assay and tumor growth delay. Histopathological changes of the tumors after various treatments were also observed with hematoxylin and eosin (H&E) staining. Necrosis and blood flow changes in the central region of tumors in the hind limbs of the animals were observed on T2-weighted imaging after an i.p. injection of 8 mg/kg of ATO alone. ATO exposure followed by radiation decreased the clonogenic survival of SCC VII cells compared with either treatment alone. Tumor growth delay after 10-20 Gy of radiation alone was increased slightly compared with control tumors, but the combination of ATO injection 2 hours before exposure to 20 Gy of radiation significantly prolonged tumor growth delay by almost 20 days. The results suggest that ATO and radiation can enhance the radiosensitivity of solid tumor.
- Open Access
- 1 January 2004
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 20 (4) , 249-255
Non-Invasive Measurement of the Temperature Using Scanning Small Coils
- 1 January 2004
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 20 (4) , 249-255
Open AccessNon-Invasive Measurement of the Temperature Using Scanning Small Coils